Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to 0.29.

  • Rhythm Pharmaceuticals' Equity Ratio rose 85179.56% to 0.29 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29, marking a year-over-year increase of 85179.56%. This contributed to the annual value of 0.06 for FY2024, which is 8914.25% down from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Equity Ratio stood at 0.29 for Q3 2025, which was up 85179.56% from 0.03 recorded in Q2 2025.
  • Rhythm Pharmaceuticals' 5-year Equity Ratio high stood at 0.91 for Q3 2021, and its period low was 0.03 during Q2 2025.
  • In the last 5 years, Rhythm Pharmaceuticals' Equity Ratio had a median value of 0.59 in 2023 and averaged 0.5.
  • The largest annual percentage gain for Rhythm Pharmaceuticals' Equity Ratio in the last 5 years was 85179.56% (2025), contrasted with its biggest fall of 13100.71% (2025).
  • Over the past 5 years, Rhythm Pharmaceuticals' Equity Ratio (Quarter) stood at 0.86 in 2021, then fell by 19.88% to 0.69 in 2022, then fell by 26.16% to 0.51 in 2023, then plummeted by 89.14% to 0.06 in 2024, then skyrocketed by 430.03% to 0.29 in 2025.
  • Its Equity Ratio stands at 0.29 for Q3 2025, versus 0.03 for Q2 2025 and 0.05 for Q1 2025.